Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

View ORCID ProfileGeorg M. N. Behrens, Joana Barros-Martins, Anne Cossmann, Gema Morillas Ramos, Metodi V. Stankov, Ivan Odak, Alexandra Dopfer-Jablonka, Laura Hetzel, Miriam Köhler, Gwendolyn Patzer, Christoph Binz, Christiane Ritter, Michaela Friedrichsen, View ORCID ProfileChristian Schultze-Florey, Inga Ravens, Stefanie Willenzon, Anja Bubke, Jasmin Ristenpart, Anika Janssen, George Ssebyatika, Günter Bernhardt, Markus Hoffmann, Stefan Pöhlmann, Thomas Krey, Berislav Bošnjak, Swantje I. Hammerschmidt, View ORCID ProfileReinhold Förster
doi: https://doi.org/10.1101/2021.12.25.21268392
Georg M. N. Behrens
1Department for Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany
2German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 30625 Hannover, Germany
3CiiM, Centre for Individualized Infection Medicine, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Georg M. N. Behrens
  • For correspondence: behrens.georg@mh-hannover.de foerster.reinhold@mh-hannover.de
Joana Barros-Martins
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Cossmann
1Department for Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gema Morillas Ramos
1Department for Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Metodi V. Stankov
1Department for Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan Odak
2German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Dopfer-Jablonka
1Department for Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany
2German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Hetzel
1Department for Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Köhler
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gwendolyn Patzer
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Binz
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Ritter
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaela Friedrichsen
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Schultze-Florey
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
5Department of Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian Schultze-Florey
Inga Ravens
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefanie Willenzon
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anja Bubke
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasmin Ristenpart
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anika Janssen
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Ssebyatika
6Institute of Biochemistry, University of Lübeck, 23562 Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Günter Bernhardt
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Hoffmann
7Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany
8Faculty of Biology and Psychology, Georg-August-University Göttingen, 37073 Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Pöhlmann
7Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany
8Faculty of Biology and Psychology, Georg-August-University Göttingen, 37073 Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Krey
5Department of Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany
9German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig and Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berislav Bošnjak
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Swantje I. Hammerschmidt
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reinhold Förster
2German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 30625 Hannover, Germany
4Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany
10Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, 30625 Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Reinhold Förster
  • For correspondence: behrens.georg@mh-hannover.de foerster.reinhold@mh-hannover.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Reports suggest that COVID-19 vaccine effectiveness is decreasing, either due to waning immune protection, emergence of new variants of concern, or both. Heterologous prime/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) appeared to be superior in inducing protective immunity, and large scale second booster vaccination is ongoing. However, data comparing declining immunity after homologous and heterologous vaccination as well as effects of a third vaccine application after heterologous ChAd/BNT vaccination are lacking. We longitudinally monitored immunity in ChAd/ChAd (n=41) and ChAd/BNT (n=88) vaccinated individuals and assessed the impact of a second booster with BNT in both groups. The second booster greatly augmented waning anti-spike IgG but only moderately increased spike-specific CD4+ and CD8+ T cells in both groups to cell frequencies already present after the boost. More importantly, the second booster efficiently restored neutralizing antibody responses against Alpha, Beta, Gamma, and Delta, but neutralizing activity against B.1.1.529 (Omicron) stayed severely impaired. Our data suggest that inferior SARS-CoV-2 specific immune responses after homologous ChAd/ChAd vaccination can be cured by a heterologous BNT vaccination. However, prior heterologous ChAd/BNT vaccination provides no additional benefit for spike-specific T cell immunity or neutralizing Omicron after the second boost.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the German Center for Infection Research TTU 01.938 (grant no 80018019238 to G.M.N.B and R.F.), and TTU 04.820 to G.M.N.B., by Deutsche Forschungsgemeinschaft, (DFG, German Research Foundation) Excellence Strategy EXC 2155 RESIST (Project ID39087428 to R.F.), by funds of the State of Lower Saxony (14-76103-184 CORONA-11/20 to R.F.), by funds of the BMBF (NaFoUniMedCovid19 FKZ: 01KX2021; Projects B-FAST to R.F.) and Deutsche Forschungsgemeinschaft, SFB 900/3 (Projects B1, 158989968 to R.F.), and the European Regional Development Fund (Defeat Corona, ZW7-8515131 and ZW7-85151373 to G.M.N.B.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The CoCo Study and the analysis conducted for this article were approved by the Internal Review Board of Hannover Medical School (institutional review board no. 8973_BO-K_2020, amendment Dec 2020).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 27, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Georg M. N. Behrens, Joana Barros-Martins, Anne Cossmann, Gema Morillas Ramos, Metodi V. Stankov, Ivan Odak, Alexandra Dopfer-Jablonka, Laura Hetzel, Miriam Köhler, Gwendolyn Patzer, Christoph Binz, Christiane Ritter, Michaela Friedrichsen, Christian Schultze-Florey, Inga Ravens, Stefanie Willenzon, Anja Bubke, Jasmin Ristenpart, Anika Janssen, George Ssebyatika, Günter Bernhardt, Markus Hoffmann, Stefan Pöhlmann, Thomas Krey, Berislav Bošnjak, Swantje I. Hammerschmidt, Reinhold Förster
medRxiv 2021.12.25.21268392; doi: https://doi.org/10.1101/2021.12.25.21268392
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Georg M. N. Behrens, Joana Barros-Martins, Anne Cossmann, Gema Morillas Ramos, Metodi V. Stankov, Ivan Odak, Alexandra Dopfer-Jablonka, Laura Hetzel, Miriam Köhler, Gwendolyn Patzer, Christoph Binz, Christiane Ritter, Michaela Friedrichsen, Christian Schultze-Florey, Inga Ravens, Stefanie Willenzon, Anja Bubke, Jasmin Ristenpart, Anika Janssen, George Ssebyatika, Günter Bernhardt, Markus Hoffmann, Stefan Pöhlmann, Thomas Krey, Berislav Bošnjak, Swantje I. Hammerschmidt, Reinhold Förster
medRxiv 2021.12.25.21268392; doi: https://doi.org/10.1101/2021.12.25.21268392

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (323)
  • Neurology (2785)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)